Founded
Address
5AM Venture Management LLC
Waltham Woods Corporate Center
Suite 140 890 Winter Street
Waltham, MA 02451
United States
Phone
Email
Website
Recent investment activity
KANDO id: 36292
Corporate information
Official name
5AM Venture Management Limited Liability Company
Also known as
5AM Ventures
Registration country
Funds managed
| Fund | Type | Vintage | Currency | Committed capital |
|---|---|---|---|---|
| 5AM Ventures V LP | Venture | 2016 | USD | 285,000,000 |
| 5AM Co-investors IV LP | Venture | 2013 | USD | 10,000,000 |
| 5AM Co-investors III LP | Venture | 2010 | USD | 5,485,000 |
| 5AM Ventures III LP | Venture | 2009 | USD | 197,825,000 |
| 5AM Ventures II LP | Venture | 2006 | USD | 150,000,000 |
| 5AM Ventures LP | Venture | 2002 | USD | 65,000,000 |
| 5AM Ventures IV LP | Venture |
Funding rounds
| Investor | Profile | Country | |
|---|---|---|---|
|
Versant Ventures Management LLC | Venture capital firm focused on making investments in the healthcare and biotechnology industries. |
Actual initial investment stage
N/A (1)
Investment activity status
Active investor
Selected investments
Displaying 1 - 25 of 34| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Anaphore Inc | Developing a novel class of protein therapeutics, Atrimers, to address significant unmet medical needs in immune-mediated diseases and oncology. | N/A USD 3,300,000 (USD 3,300,000) | |||
|
|
Ceterix Orthopedics Inc | Develops technologies to address unmet clinical needs in arthroscopic surgery | Series A | |||
|
|
DVS Sciences Inc | An analytical instrument and reagents company founded in Toronto | Series A | |||
|
|
Envoy Therapeutics Inc | A platform CNS drug discovery company spun out of decades of work at the Rockefeller University | N/A | |||
|
|
Flexion Therapeutics Inc | Discovers and develops innovative therapeutics for musculoskeletal disorders | Series A | |||
|
|
Fourteen22 | A biopharmaceutical company, focused on developing biosimilar monoclonal antibodies | N/A | |||
|
|
Igenica Inc | A monoclonal-antibody discovery and development company | Series B | |||
|
|
Ikaria Inc | Developer of innovative therapeutics and interventions to meet the significant needs of critically ill patients | N/A | |||
|
|
Ilypsa Inc | Discover and develop new polymer-based therapeutics | N/A | |||
|
|
Incline Therapeutics Inc | Patient controlled analgesia | Series A | |||
|
|
KaloBios Pharmaceuticals Inc | Develops first- or best-in-class antibody therapeutics in the fields of autoimmunity | N/A | |||
|
|
Kinestral Technologies Inc | Industrial biotechnology company developing novel new chemistry applied to building materials for energy efficiency. | N/A | |||
|
|
Miikana Therapeutics Inc | A clinically-driven oncology company founded out of the former Amgen Institute | N/A | |||
|
|
Panomics Inc | Develops novel cell-based assays and tools to enable multiplexed measurements of molecular events in a quantitative and scalable manner | N/A | |||
|
|
Pearl Therapeutics Inc | Developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases | N/A | |||
|
|
Pearl Therapeutics Inc | Developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases | Series A | |||
|
|
PhaseRx Inc | Develops novel approaches to the delivery of siRNA and other macromolecules | Series A | |||
|
|
Pulmatrix Inc | Discovering a new class of host-targeted therapies that pathogen independently treat | Series A | |||
|
|
Relypsa Inc | Leads the discovery and development of new non-absorbed polymeric drugs | Series A | |||
|
|
Rennovia Inc | Developing processes to make high-value known chemicals derived from renewable bio sources that have both financial and green advantages | Series A | |||
|
|
Semprus BioSciences | Develops implantable and permanently-antimicrobial surface technology that is incorporated into medical devices | Series B | |||
|
|
Semprus BioSciences | Develops implantable and permanently-antimicrobial surface technology that is incorporated into medical devices | Series A | |||
|
|
Synosia Therapeutics | Develops innovative treatments for disorders of the central nervous system | Series B | |||
|
|
Synosia Therapeutics | Develops innovative treatments for disorders of the central nervous system | N/A | |||
|
|
Variation Biotechnologies (US) Inc | A vaccine development company dedicated to the innovative formulation | N/A |
Team
| Employee | Position | |||
|---|---|---|---|---|
| John Diekman (founder) | [email protected] | |||
| Scott Rocklage (founder) | [email protected] | |||
| Andrew Schwab | [email protected] | |||
| Mason Freeman | ||||
| James Young |